| Literature DB >> 29112138 |
Weiyi Wang1,2,3, Yanyan Liao4,5,6, Chao Tang7,8,9, Xiaomei Huang10,11,12, Zhuhua Luo13, Jianming Chen14,15, Peng Cai16,17,18.
Abstract
Three novel compounds, 4-methyl-candidusin A (1), aspetritone A (2) and aspetritone B (3), were obtained from the culture of a coral-derived fungus Aspergillus tritici SP2-8-1, together with fifteen known compounds (4-18). Their structures, including absolute configurations, were assigned based on NMR, MS, and time-dependent density functional theory (TD-DFT) ECD calculations. Compounds 2 and 5 exhibited better activities against methicillin-resistant strains of S. aureus (MRSA) ATCC 43300 and MRSA CGMCC 1.12409 than the positive control chloramphenicol. Compound 5 displayed stronger anti-MRSA and lower cytotoxic activities than 2, and showed stronger antibacterial activities against strains of Vibrio vulnificus, Vibrio rotiferianus, and Vibrio campbellii than the other compounds. Compounds 2 and 10 exhibited significantly stronger cytotoxic activities against human cancer cell lines HeLa, A549, and Hep G2 than the other compounds. Preliminary structure-activity relationship studies indicated that prenylation of terphenyllin or candidusin and the tetrahydrobenzene moiety in anthraquinone derivatives may influence their bioactivity.Entities:
Keywords: Aspergillus; antibacterial; aspetritone; candidusin; cytotoxic
Mesh:
Substances:
Year: 2017 PMID: 29112138 PMCID: PMC5706038 DOI: 10.3390/md15110348
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1Structure of compounds 1–18.
1H NMR data (400 MHz) and 13C NMR data (100 MHz) for compounds 1–3.
| Position | 1 | 2 | 3 | |||
|---|---|---|---|---|---|---|
| δH, mult. ( | δC | δH, mult. ( | δC | δH, mult. ( | δC | |
| 1 | 114.9 | 4.26, d (7.03) | 73.8 | 2.54, dd (19.84, 4.88), Heq | 30.1 | |
| 2 | 7.39, s | 107.3 | 3.13, m | 76.3 | 3.59, m | 69.7 |
| 3 | 144.0 | 1.76, m | 33.5 | 69.1 | ||
| 4 | 148.4 | 2.19, dd (18.45, 11.46), Hax | 31.3 | 2.45, br d (13.30) | 33.0 | |
| 5 | 7.38, s | 96.6 | 187.2 | 155.1 | ||
| 6 | 149.7 | 148.8 | 140.8 | |||
| 7 | 146.9 | 157.9 | ||||
| 8 | 181.1 | 7.16, s | 104.0 | |||
| 9 | 7.65, s | 118.1 | 183.5 | |||
| 10 | 158.0 | 189.2 | ||||
| 11 | 111.0 | 110.8 | ||||
| 12 | 128.5 | 127.9 | ||||
| 13 | 148.6 | 142.8 | ||||
| 14 | 131.7 | 142.6 | ||||
| 1′ | 114.2 | |||||
| 2′ | 149.0 | |||||
| 3′ | 136.4 | |||||
| 4′ | 131.4 | |||||
| 5′ | 6.72, s | 106.0 | ||||
| 6′ | 150.0 | |||||
| 1″ | 129.0 | |||||
| 2″, 6″ | 7.42, d (8.53) | 130.8 | ||||
| 3″, 5″ | 6.85, d (8.53) | 115.5 | ||||
| 4″ | 157.2 | |||||
| CH3-3 | 1.08, d (6.53) | 18.5 | 1.21, s | 26.0 | ||
| OCH3-4 | 3.87, s | 56.4 | ||||
| OCH3-6 | 3.99, s | 61.4 | 3.79, s | 60.8 | ||
| OCH3-7 | 3.95, s | 61.7 | 3.92, s | 56.8 | ||
| OCH3-3′ | 3.77, s | 61.0 | ||||
| OCH3-6′ | 3.97, s | 56.3 | ||||
| OH-1 | 5.82, d (6.27) | |||||
| OH-2 | 5.06, d (5.02) | 4.73, br s | ||||
| OH-3 | 9.06, brs | 5.03, br s | ||||
| OH-5 | 12.09, s | |||||
| OH-10 | 12.18, s | |||||
| OH-4″ | 9.55, brs | |||||
Figure 2Key COSY and HMBC correlations of compounds 1–3.
Figure 3Key NOESY correlations of compounds 2 and 3.
Figure 4Calculated and Experimental ECD of compounds 2 and 3.
Antibacterial and cytotoxic activities of compounds 1–18. Data are expressed as mean ± SD values of three independent experiments, each made in triplicate.
| Compound | MIC (μg/mL) | IC50 (μM) | ||||||
|---|---|---|---|---|---|---|---|---|
| MRSA 1 | MRSA 2 | VV | VR | VC | HeLa | A549 | Hep G2 | |
| 1 | 31.33 ± 0.61 | 30.97 ± 0.78 | 31.47 ± 1.22 | NA | 15.10 ± 0.44 | 30.23 ± 1.32 | 24.53 ± 1.10 | 27.50 ± 1.57 |
| 2 | 15.61 ± 0.48 | 31.17 ± 0.35 | 15.53 ± 0.60 | |||||
| 3 | 15.27 ± 0.35 | 15.63 ± 0.45 | 15.47 ± 0.51 | 31.33 ± 0.23 | 15.77 ± 0.29 | 10.57 ± 0.93 | 4.67 ± 0.60 | 8.57 ± 0.83 |
| 4 | 15.67 ± 0.50 | 7.57 ± 0.73 | 15.58 ± 0.33 | 15.57 ± 0.30 | NA | 16.77 ± 0.45 | 21.07 ± 0.76 | 27.17 ± 0.29 |
| 5 | 15.57 ± 0.30 | 10.20 ± 0.50 | 13.07 ± 0.72 | 35.10 ± 1.00 | ||||
| 6 | NA | NA | NA | NA | NA | NA | NA | NA |
| 7 | 31.47 ± 0.24 | 31.23 ± 0.10 | 31.42 ± 0.23 | 31.33 ± 0.19 | NA | 25.07 ±0.81 | 19.07 ± 0.64 | 32.10 ± 2.00 |
| 8 | NA | NA | NA | NA | NA | NA | NA | NA |
| 9 | 31.30 ± 0.26 | 31.45 ± 0.22 | 31.37 ± 0.14 | 31.53 ± 0.31 | 31.47 ± 0.25 | NA | NA | NA |
| 10 | 15.53 ± 0.31 | 15.47 ± 0.23 | 31.43 ± 0.32 | 31.37 ± 0.21 | NA | |||
| 11 | 31.47 ± 0.24 | 31.27 ± 0.16 | 31.37 ± 0.25 | NA | NA | 18.87 ± 1.27 | 12.33 ± 0.68 | 21.2 ± 0.35 |
| 12 | 31.30 ± 0.17 | 31.33 ± 0.12 | 31.43 ± 0.21 | NA | NA | 23.37 ± 0.84 | 36.07 ± 1.67 | 32.10 ± 2.65 |
| 13 | NA | NA | NA | NA | NA | NA | NA | 45.20 ± 1.00 |
| 14 | 31.33 ± 0.23 | 31.28 ± 0.10 | 31.25 ± 0.13 | NA | 31.43 ± 0.20 | 38.30 ± 1.50 | NA | 40.10 ± 0.90 |
| 15 | 15.65 ± 0.18 | 15.53 ± 0.12 | 15.73 ± 0.12 | 62.67 ± 0.15 | 31.35 ± 0.22 | 25.07 ± 0.81 | 22.17 ± 1.45 | 30.20 ± 0.87 |
| 16 | 31.32 ± 0.25 | 31.33 ± 0.23 | NA | NA | NA | NA | NA | NA |
| 17 | NA | NA | NA | 31.28 ± 0.14 | NA | NA | 45.63 ± 1.79 | NA |
| 18 | NA | NA | NA | NA | NA | NA | NA | 42.07 ± 1.07 |
| erythromycin | NT | NT | 1.92 ± 0.06 | 3.93 ± 0.03 | 7.68 ± 0.10 | NT | NT | NT |
| chloramphenicol | 7.67 ± 0.13 | 7.87 ± 0.08 | NT | NT | NT | NT | NT | NT |
| doxorubicin | NT | NT | NT | NT | NT | 0.50 ± 0.05 | 0.09 ± 0.01 | 1.06 ± 0.07 |
MRSA 1: methicillin-resistant S. aureus ATCC 43300; MRSA 2: methicillin-resistant S. aureus CGMCC 1.12409; VV: V. vulnificus MCCC E1758; VR: V. rotiferianus MCCC E385; VC: V. campbellii MCCC E333; NA: no activity at the concentration of 50 μg/mL (antibacterial) or 50 μM (cytotoxic); NT: not tested.